Cost-Effectiveness Analysis of Six Immunotherapy-Based Regimens and Sunitinib in Metastatic Renal Cell Carcinoma: A Public Payer Perspective.
Minkyoung YooRichard E NelsonZachary A CutshallMaura DoughertyManish KohliPublished in: JCO oncology practice (2023)
NI was the most effective combination for mRCC, but at a willingness-to-pay threshold of $150,000 USD/QALY, sunitinib was the most cost-effective approach.